• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Critical reviews in oncogenesis >The role for transforming growth factor-beta (TGF-beta) in human cancer.
【24h】

The role for transforming growth factor-beta (TGF-beta) in human cancer.

机译：在人类癌症中转化生长因子-β（TGF-β）的作用。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Uncontrolled cellular proliferation is a hallmark of cancer. Thus, a relevant and important question is how cancer cells have escaped from normal growth regulatory mechanisms to become malignant and, further, what events favor progression and metastasis. Growth regulatory proteins of the transforming growth factor-beta family (TGF-beta) are one of the few classes of endogenous inhibitors of cell growth. Contrary to the first notion that these proteins may be downregulated in cancer cells to promote their growth, generally it has been otherwise found that there is a marked increase in the expression of TGF-beta mRNA and protein in human cancers (in vivo), including those of the pancreas, colon, stomach, lung, endometrium, prostate, breast, brain, and bone. Furthermore, in many of these cancers high expression correlates with more advanced stages of malignancy and decreased survival. The increased expression of TGF-beta is usually accompanied by a loss in the growth inhibitory response to TGF-beta. For example, certain tumor cells in culture (i.e., colon carcinoma and glioblastoma multiforme) demonstrate a progressive loss of the growth inhibitory response to TGF-beta that varies directly with the malignant stage of the original tumor, and the most aggressive forms actually switch to being autocrine and/or paracrine growth stimulated by TGF-beta. The study of the molecular events associated with the escape of tumor cells from growth regulation by TGF-beta has provided insight into mechanisms underlying carcinogenesis. The mechanisms for upregulation of TGF-beta are unknown. However, once malignant cells lose their growth inhibitory response to TGF-beta and produce massive amounts of these proteins, the increased expression of TGF-beta provides a selective advantage for tumor cell survival as TGF-betas are also angiogenic and have potent immunosuppressive effects, including specifically inhibiting tumoricidal natural and lymphocyte-activated killer cells. In light of the significant role for TGF-betas in regulating cell growth, it is not surprising that in more recent years studies have shown that specific genetic alterations involved in the signaling pathway for TGF-beta-mediated growth inhibition have occurred in many human cancers. Specific defects in TGF-beta receptors, TGF-beta-related-signal transduction/gene activation, and TGF-beta-regulated cell cycle proteins, have all been implicated in the oncogenesis of many human cancers. In this context, components of the TGF-beta growth response pathway are considered to be tumor suppressor genes, as absence (or malfunction) of one or more receptors or signaling proteins would have the potential to cause loss of growth regulation. More recently, the posttranslational reduction of levels of the cyclin-dependent kinase inhibitor (CKI), p27kip1, which mediates TGF-beta growth inhibition, provides an additional means for cancer cells to escape negative growth regulation by TGF-beta. This review provides background information on TGF-beta and updates the status of our knowledge of the role for TGF-beta in specific human malignancies. Understanding the molecular events involved in TGF-beta function in normal cells and its lack of function in tumor cells should identify novel therapeutic targets in human cancers.
机译：不受控制的细胞增殖是癌症的标志。因此，一个相关且重要的问题是癌细胞如何从正常的生长调节机制中逃脱而变成恶性肿瘤，此外，哪些事件有利于进展和转移。转化生长因子-β家族（TGF-β）的生长调节蛋白是细胞生长的内源性抑制剂的少数几类之一。与第一种观念认为这些蛋白质可能在癌细胞中被下调以促进其生长相反，通常已经发现，在人类癌症（体内）中，TGF-βmRNA和蛋白质的表达显着增加，包括胰腺，结肠，胃，肺，子宫内膜，前列腺，乳房，脑和骨骼的那些。此外，在许多这些癌症中，高表达与恶性肿瘤的更晚期和存活率降低相关。 TGF-β的表达增加通常伴随着对TGF-β的生长抑制反应的丧失。例如，培养物中的某些肿瘤细胞（即结肠癌和多形性胶质母细胞瘤）表现出对TGF-β的生长抑制反应的进行性丧失，其直接随原始肿瘤的恶性程度而变化，而最具攻击性的形式实际上转变为是TGF-β刺激的自分泌和/或旁分泌生长。对与肿瘤细胞逃避TGF-β的生长调节相关的分子事件的研究，为了解潜在的致癌机制提供了见识。 TGF-β上调的机制尚不清楚。但是，一旦恶性细胞丧失了对TGF-β的生长抑制反应并产生大量这些蛋白质，TGF-β的表达增加就为肿瘤细胞的生存提供了选择性优势，因为TGF-β也是血管生成的，并且具有强大的免疫抑制作用，包括特异性抑制自然杀伤和淋巴细胞激活的杀伤细胞。鉴于TGF-β在调节细胞生长中的重要作用，不足为奇的是，最近几年的研究表明，许多人类癌症中都发生了与TGF-β介导的生长抑制的信号传导途径有关的特定基因改变。 。 TGF-β受体的特定缺陷，TGF-β-相关信号的转导/基因激活以及TGF-β调节的细胞周期蛋白，都与许多人类癌症的发生有关。在这种情况下，TGF-β生长反应途径的组成部分被认为是肿瘤抑制基因，因为一种或多种受体或信号蛋白的缺失（或功能失常）将可能导致生长调控的丧失。最近，翻译后降低的细胞周期蛋白依赖性激酶抑制剂（CKI）p27kip1的水平介导TGF-β的生长抑制，为癌细胞摆脱TGF-β的负生长调控提供了另一种手段。这篇综述提供了有关TGF-beta的背景信息，并更新了我们对TGF-beta在特定人类恶性肿瘤中的作用的了解。了解正常细胞中TGF-β功能所涉及的分子事件及其在肿瘤细胞中缺乏功能，应确定人类癌症的新治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号